Dohj LLC Purchases Shares of 857 Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Dohj LLC purchased 857 shares of Vertex Pharmaceuticals, valued at approximately $422,000, indicating growing interest from institutional investors in the company.
• Vertex Pharmaceuticals reported $4.52 earnings per share for the last quarter, exceeding analysts' expectations, with a year-over-year revenue increase of 11.3%.
• Major equity research firms have set a consensus price target of $493.81 for Vertex Pharmaceuticals, with many analysts rating the stock as a Moderate Buy.

Dohj LLC acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 857 shares of the pharmaceutical company's stock, valued at approximately $422,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Activest Wealth Management acquired a new position in Vertex Pharmaceuticals during the first quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 45 shares in the last quarter. Flaharty Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals in the first quarter valued at about $32,000. American National Bank & Trust raised its holdings in Vertex Pharmaceuticals by 515.4% during the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company's stock worth $36,000 after acquiring an additional 67 shares in the last quarter. Finally, SJS Investment Consulting Inc. boosted its position in Vertex Pharmaceuticals by 46.2% during the first quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company's stock valued at $46,000 after purchasing an additional 30 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $410.28 on Wednesday. The firm has a market cap of $105.19 billion, a price-to-earnings ratio of 29.33 and a beta of 0.43. The stock's fifty day moving average price is $396.79 and its two-hundred day moving average price is $441.11. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter last year, the firm earned ($12.83) earnings per share. The company's revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were bought at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company's stock, valued at $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.20% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on VRTX shares. Guggenheim dropped their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. Leerink Partners upgraded shares of Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating and cut their target price for the company from $458.00 to $456.00 in a research note on Thursday, September 25th. UBS Group set a $553.00 price target on Vertex Pharmaceuticals and gave the stock a "buy" rating in a research report on Tuesday, August 5th. HC Wainwright reduced their target price on Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating for the company in a research note on Tuesday, August 5th. Finally, Evercore ISI dropped their price target on Vertex Pharmaceuticals from $510.00 to $475.00 and set an "outperform" rating on the stock in a research note on Thursday, September 11th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $493.81.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.